This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Chugai Seiyaku Kabushiki Kaisha. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Hiroshi Hino: Innovator in Genetic Engineering
Introduction
Hiroshi Hino is a prominent inventor based in Shizuoka, Japan. He has made significant contributions to the field of genetic engineering, particularly in the development of genetically modified organisms. His work focuses on enhancing the understanding of human diseases through innovative research methodologies.
Latest Patents
Hiroshi Hino holds a patent for a gene-modified mouse expressing human GPC3 polypeptide. This invention involves genetically modified non-human animals that are deficient in the expression of an endogenous GPC3 polypeptide and express a human GPC3 polypeptide at a physiologically adequate level. The patent outlines methods for producing these non-human animals and evaluating test substances using them. Furthermore, it includes methods for assessing the safety and therapeutic effects of substances on diseases, pharmacokinetics, and in vivo distribution, utilizing these non-human animals as models.
Career Highlights
Hiroshi Hino is associated with Chugai Seiyaku Kabushiki Kaisha, a leading pharmaceutical company in Japan. His work at the company has been instrumental in advancing research in genetic modifications and their applications in medicine. His innovative approaches have garnered attention in the scientific community.
Collaborations
Hiroshi has collaborated with notable colleagues, including Koichi Jishage and Yasuko Kinoshita. These partnerships have contributed to the success of his research and the development of groundbreaking technologies in genetic engineering.
Conclusion
Hiroshi Hino's contributions to genetic engineering and his innovative patent for a gene-modified mouse exemplify the potential of genetic research in understanding human health. His work continues to inspire advancements in the field and holds promise for future medical applications.